Quarterly Result25 May 2026, 09:31 pm
Aarti Pharmalabs: FY26 Revenue ₹1797.55 Mn, PAT ₹176.2 Mn
AI Summary
Aarti Pharmalabs Ltd's board approved the audited financial results for the quarter and financial year ended March 31, 2026. The company reported revenue from operations (net) of ₹1797.55 million and a net profit of ₹176.2 million for FY26. A final dividend of ₹2 per equity share of face value ₹5 each was recommended, subject to shareholder approval. Smt. Ketki D. Visariya was re-appointed as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY 2026-27. Mr. Sachin Patil and Mr. Rajendra Pagare were designated as Senior Management Personnel.
Key Highlights
- Aarti Pharmalabs' FY26 revenue from operations (net) stood at ₹1797.55 million.
- The company's net profit for FY26 was reported as ₹176.2 million.
- A final dividend of ₹2 per equity share has been recommended for FY26.
- Sachin Patil and Rajendra Pagare designated as Senior Management Personnel.
- Cost and Internal Auditors re-appointed for the financial year 2026-27.
Price Impact
More from AARTIPHARM